These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 10570748

  • 1. Immune rejection of intracerebral gliomas using lymphocytes from glioma-bearing rats.
    Wood GW, Turner T, Wang YY, Holladay FP.
    J Immunother; 1999 Nov; 22(6):497-505. PubMed ID: 10570748
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP, Heitz T, Wood GW.
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [Abstract] [Full Text] [Related]

  • 3. Generation of cytotoxic immune responses during the progression of a rat glioma.
    Holladay FP, Choudhuri R, Heitz T, Wood GW.
    J Neurosurg; 1994 Jan; 80(1):90-6. PubMed ID: 8271027
    [Abstract] [Full Text] [Related]

  • 4. Generation of cellular immune responses against a glioma-associated antigen(s).
    Holladay FP, Wood GW.
    J Neuroimmunol; 1993 Apr; 44(1):27-32. PubMed ID: 8496337
    [Abstract] [Full Text] [Related]

  • 5. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.
    Holladay FP, Lopez G, De M, Morantz RA, Wood GW.
    Neurosurgery; 1992 Apr; 30(4):499-504; discussion 504-5. PubMed ID: 1584347
    [Abstract] [Full Text] [Related]

  • 6. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.
    Baldwin NG, Rice CD, Tuttle TM, Bear HD, Hirsch JI, Merchant RE.
    J Neurooncol; 1997 Mar; 32(1):19-28. PubMed ID: 9049859
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
    Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G.
    Neurosurg Focus; 2000 Dec 15; 9(6):e9. PubMed ID: 16817692
    [Abstract] [Full Text] [Related]

  • 9. Glioma antigen.
    Toda M.
    Adv Exp Med Biol; 2012 Dec 15; 746():77-84. PubMed ID: 22639160
    [Abstract] [Full Text] [Related]

  • 10. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
    Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-DeMasters B, Bellgrau D.
    Proc Natl Acad Sci U S A; 1990 Dec 15; 87(24):9577-81. PubMed ID: 2263613
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mechanisms of local immunoresistance in glioma.
    Albesiano E, Han JE, Lim M.
    Neurosurg Clin N Am; 2010 Jan 15; 21(1):17-29. PubMed ID: 19944963
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mesenchymal Stromal Stem Cell-Derived Microvesicles Enhance Tumor Lysate Pulsed Dendritic Cell Stimulated Autologous T lymphocyte Cytotoxicity.
    Rahmani Kukia N, Alipanah-Moghadam R, Delirezh N, Mazani M.
    Asian Pac J Cancer Prev; 2018 Jul 27; 19(7):1895-1902. PubMed ID: 30049202
    [Abstract] [Full Text] [Related]

  • 16. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H.
    Gene Ther; 2004 Nov 27; 11(21):1551-8. PubMed ID: 15343358
    [Abstract] [Full Text] [Related]

  • 17. Cellular immunotherapy for malignant gliomas.
    Lin Y, Okada H.
    Expert Opin Biol Ther; 2016 Oct 27; 16(10):1265-75. PubMed ID: 27434205
    [Abstract] [Full Text] [Related]

  • 18. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.
    Rice CD, Baldwin NG, Biron RT, Bear HD, Merchant RE.
    J Neurooncol; 1997 Mar 27; 32(1):29-38. PubMed ID: 9049860
    [Abstract] [Full Text] [Related]

  • 19. Specific adoptive immunotherapy of malignant glioma with long-term cytotoxic T lymphocyte line expanded in T-cell growth factor. Experimental study and future prospects.
    Yamasaki T, Handa H, Yamashita J, Watanabe Y, Namba Y, Hanaoka M.
    Neurosurg Rev; 1984 Mar 27; 7(1):37-54. PubMed ID: 6611523
    [Abstract] [Full Text] [Related]

  • 20. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ, Barth RF, Clendenon NR, Gordon WA.
    Cancer Res; 1990 Jul 15; 50(14):4338-43. PubMed ID: 2364388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.